These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21208155

  • 1. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia.
    Tancevski I, Demetz E, Eller P.
    Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):16-9. PubMed ID: 21208155
    [Abstract] [Full Text] [Related]

  • 2. The resurgence of thyromimetics as lipid-modifying agents.
    Tancevski I, Eller P, Patsch JR, Ritsch A.
    Curr Opin Investig Drugs; 2009 Sep; 10(9):912-8. PubMed ID: 19705333
    [Abstract] [Full Text] [Related]

  • 3. Sobetirome: the past, present and questions about the future.
    Lammel Lindemann J, Webb P.
    Expert Opin Ther Targets; 2016 Sep; 20(2):145-9. PubMed ID: 26565124
    [Abstract] [Full Text] [Related]

  • 4. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
    Delitala AP, Delitala G, Sioni P, Fanciulli G.
    Curr Med Res Opin; 2017 Nov; 33(11):1985-1993. PubMed ID: 28498022
    [Abstract] [Full Text] [Related]

  • 5. Lipid lowering with thyroid hormone and thyromimetics.
    Angelin B, Rudling M.
    Curr Opin Lipidol; 2010 Dec; 21(6):499-506. PubMed ID: 20935564
    [Abstract] [Full Text] [Related]

  • 6. [Thyroid hormone analogs: an important biological supply and new therapeutic possibilities].
    Josseaume C, Lorcy Y.
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S33-6. PubMed ID: 18954857
    [Abstract] [Full Text] [Related]

  • 7. Sobetirome: a case history of bench-to-clinic drug discovery and development.
    Scanlan TS.
    Heart Fail Rev; 2010 Mar; 15(2):177-82. PubMed ID: 19002578
    [Abstract] [Full Text] [Related]

  • 8. The thyroid receptor β modulator GC-1 reduces atherosclerosis in ApoE deficient mice.
    Kannisto K, Rehnmark S, Slätis K, Webb P, Larsson L, Gåfvels M, Eggertsen G, Parini P.
    Atherosclerosis; 2014 Dec; 237(2):544-54. PubMed ID: 25463087
    [Abstract] [Full Text] [Related]

  • 9. Novel agents to manage dyslipidemias and impact atherosclerosis.
    Nachimuthu S, Raggi P.
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):209-17. PubMed ID: 17017903
    [Abstract] [Full Text] [Related]

  • 10. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice.
    Johansson L, Rudling M, Scanlan TS, Lundåsen T, Webb P, Baxter J, Angelin B, Parini P.
    Proc Natl Acad Sci U S A; 2005 Jul 19; 102(29):10297-302. PubMed ID: 16006512
    [Abstract] [Full Text] [Related]

  • 11. Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples.
    Devereaux J, Ferrara SJ, Scanlan TS.
    Methods Mol Biol; 2018 Jul 19; 1801():193-206. PubMed ID: 29892826
    [Abstract] [Full Text] [Related]

  • 12. Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
    Elbers LP, Kastelein JJ, Sjouke B.
    Curr Atheroscler Rep; 2016 Mar 19; 18(3):14. PubMed ID: 26886134
    [Abstract] [Full Text] [Related]

  • 13. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Mar 19; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 14. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
    Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD.
    Proc Natl Acad Sci U S A; 2008 Jan 15; 105(2):663-7. PubMed ID: 18160532
    [Abstract] [Full Text] [Related]

  • 15. The Thyromimetic Sobetirome (GC-1) Alters Bile Acid Metabolism in a Mouse Model of Hepatic Cholestasis.
    Kosar K, Cornuet P, Singh S, Liu S, Nejak-Bowen K.
    Am J Pathol; 2020 May 15; 190(5):1006-1017. PubMed ID: 32205094
    [Abstract] [Full Text] [Related]

  • 16. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
    Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G.
    Front Med (Lausanne); 2020 May 15; 7():331. PubMed ID: 32733906
    [Abstract] [Full Text] [Related]

  • 17. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R, Di Pino A, Ferrara V, Urbano F, Piro S, Rabuazzo AM, Purrello F.
    Acta Diabetol; 2018 Mar 15; 55(3):209-218. PubMed ID: 29260404
    [Abstract] [Full Text] [Related]

  • 18. Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics.
    Ferrara SJ, Bourdette D, Scanlan TS.
    Endocrinology; 2018 Jul 01; 159(7):2733-2740. PubMed ID: 29846550
    [Abstract] [Full Text] [Related]

  • 19. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome.
    Yamaoka-Tojo M, Tojo T, Izumi T.
    Curr Vasc Pharmacol; 2008 Oct 01; 6(4):271-81. PubMed ID: 18855715
    [Abstract] [Full Text] [Related]

  • 20. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, Perk J, Hajage D, Henriksson KM, Borghi C.
    BMC Cardiovasc Disord; 2017 Jun 17; 17(1):160. PubMed ID: 28623902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.